MEMBRANEBLUE
LOE Approachingtrypan blue
NDAOPHTHALMICSOLUTIONPriority Review
Approved
Feb 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
MEMBRANEBLUE (trypan blue) is membraneblue 0. First approved in 2009.
Drug data last refreshed 2d ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MembraneBlue (trypan blue 0.15%) is an ophthalmic solution used during posterior segment eye surgery to selectively stain epiretinal membranes (ERM) and internal limiting membranes (ILM), improving surgeon visualization during membrane peeling procedures. It works by binding to and highlighting these ocular membranes, enabling safer and more precise surgical removal. The product serves as a vital surgical aid in vitreoretinal procedures.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity, suggesting potential contraction in brand team size and focus shifting toward generic preparation or product transition.
Mechanism of Action
MembraneBlue 0.15% - Mechanism of action section. MembraneBlue 0.15% selectively stains membranes in the human eye during posterior surgery, such as epiretinal membranes (ERM) and Internal Limiting Membranes (ILM).
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MembraneBlue is linked to only 1 active job opening, predominantly in technical manufacturing (Cell Culture Technician I), reflecting a small, specialized team footprint. Working on this product offers exposure to surgical ophthalmic markets and specialist sales environments, but limited opportunities for team expansion or career ladder advancement given the approaching LOE stage.
Cell Culture Technician I
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.